ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease

Author(s): Hamad, N; Bilmon, I; Chee, L; Henden, A; Johnston, A; Purtill, D; Bajel, A; Tey, SK; Yeung, D; Cole, T; Lewis, C; Butler, J;
Details: Publication Year 2023-12,Volume 53,Issue #12,Page 2319-2329
Journal Title: Internal Medicine Journal
Publication Type: Guideline
Abstract: This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.
Publisher: Wiley
Keywords: Humans; *Bronchiolitis Obliterans Syndrome; Consensus; *Hematopoietic Stem Cell Transplantation; Steroids/therapeutic use; Nitriles; Adrenal Cortex Hormones/therapeutic use; *Graft vs Host Disease/drug therapy; Acute Disease; Chronic Disease; GvHD; acute; chronic; graft-versus-host disease; ruxolitinib
Department(s): Clinical Haematology
Publisher's Version: https://doi.org/10.1111/imj.16255
Open Access at Publisher's Site: https://doi.org/10.1111/imj.16255
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-01-18 07:06:24

Last Modified: 2024-01-18 07:06:48